<DOC>
	<DOCNO>NCT00322101</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , fludarabine phosphate , busulfan , cyclophosphamide , total-body radiation therapy donor peripheral stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . It yet know whether low-dose chemotherapy total-body radiation therapy effective high-dose chemotherapy treat patient myelodysplastic syndrome acute myeloid leukemia . PURPOSE : This phase III trial study low-dose conditioning see well work compare high-dose conditioning follow peripheral blood stem cell transplant treat patient myelodysplastic syndrome acute myeloid leukemia</brief_summary>
	<brief_title>Low-Dose High-Dose Conditioning Followed Peripheral Blood Stem Cell Transplant Treating Patients With Myelodysplastic Syndrome Acute Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether condition intensity affect outcomes HCT patient MDS AML &lt; 5 % marrow myeloblast time HCT . OUTLINE : Patients randomize 1 2 treatment arm . Arm I ( Nonmyeloablative regimen ) : CONDITIONING : Patients receive fludarabine phosphate IV day -4 -2 undergo low-dose total-body irradiation day 0 . TRANSPLANTATION : Patients undergo allogeneic peripheral blood stem cell ( PBSC ) infusion day 0 . GRAFT-VS-HOST DISEASE PROPHYLAXIS : Patients receive cyclosporine every 12 hour day -3 57 taper day 57-177 cyclosporine every 12 hour day -3 100 taper day 101-177 . Patients also receive oral mycophenolate mofetil every 12 hour day 0-27 every 8 hour day 0-40 taper day 41-96 . Arm II ( Myeloablative regimen ) : CONDITIONING : Patients assign 1 2 treatment group . Group A : Patients receive fludarabine IV daily oral busulfan four time daily busulfan IV 3 hour day -5 -2 . Group B : Patients receive cyclophosphamide IV 1-2 hour day -3 -2 oral busulfan four time daily busulfan IV 3 hour day -7 -4 . TRANSPLANTATION : Patients undergo PBSC infusion day 0 . GRAFT-VS-HOST DISEASE PROPHYLAXIS : Patients receive tacrolimus IV continuously orally every 12 hour day -1 56 taper day 57-200 . Patients also receive methotrexate IV day 1 , 3 , 6 , 11 . Treatment arm continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Leukemoid Reaction</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Myelodysplastic syndrome ( MDS ) transform acute myelogenous leukemia ( transformed MDS ) De novo acute myelogenous leukemia ( AML ) beyond first remission Intermediate high risk de novo AML first complete response ( FHCRC unrelated donor recipient ) Chemotherapy require prior HCT patient : A ) Interval start cycle cytoreductive chemotherapy infusion donor stem cell must least 30 day ; chemotherapy receive disease maintenance allow time period B ) All patient must &lt; 5 % myeloblast base marrow morphology perform within 21 day prior start condition regimen least 34 week start pretransplant cytoreductive chemotherapy C ) All patient must circulate peripheral blood myeloblast present base morphologic analysis Age 65 year patient related donor ; age 60 year patient unrelated donor HCTSpecific Comorbidity Index Score ( HCTCI ) &lt; 3 Related donor ( age &gt; 12 year , nonsyngeneic ) unrelated donor , HLA phenotypically genotypically identical allele level A , B , C , DRQ1 , CBQ1 DONOR : Related unrelated donor genotypically phenotypically match high resolution HLA typing ( HLAA , B , C , DRB1 , DQB1 ) ; class 1 single allele mismatch allow DONOR : Patient donor pair homozygous mismatch allele graft rejection vector consider twoallele mismatch , i.e. , patient A*0101 donor A*0201 , type mismatch allow DONOR : A positive antidonor cytotoxic crossmatch flow cytometric assay absolute donor exclusion FHCRC/SCCA DONOR : Age &gt; = 12 year DONOR : Donors must consent PBSC mobilization GCSF leukaphereses ; bone marrow source stem cell allow DONOR : Donor must adequate vein leukaphereses agree placement central venous catheter ( femoral , subclavian ) HIV seropositivity Fungal infection radiographic progression appropriate therapy great one month Organ dysfunction Symptomatic coronary artery disease ejection fraction &lt; 35 % DLCO &lt; 65 % , FEV1 &lt; 65 % receive supplementary continuous oxygen Liver function abnormality : Patients clinical laboratory evidence liver disease evaluate cause liver disease , clinical severity term liver function , histology , degree portal hypertension ; patient fulminant liver failure , cirrhosis evidence portal hypertension bridge fibrosis , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease exclude Karnofsky Performance Score &lt; 70 LanskyPlay Performance Score &lt; 70 pediatric patient Life expectancy severely limited ( &lt; 2 year ) disease MDS/AML Fertile men woman unwilling use contraceptive technique 12 month follow treatment Patients active nonhematological malignancy except : A ) Patients follicular low grade lymphoma eligible long require active treatment control disease B ) Patients localized nonmelanoma skin malignancy Patients poorly control hypertension unable blood pressure stabilize 150/90 mm Hg standard medication Females pregnant breastfeeding Patients systemic , uncontrolled infection Active CNS disease identify positive CSF cytospin DONOR : Identical twin DONOR : Age &lt; 12 year DONOR : Pregnancy DONOR : HIV seropositivity DONOR : Inability achieve adequate venous access DONOR : Known adverse reaction GCSF</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>